Apogee Therapeutics (APGE) analyst forecast and price target
Analyst forecast
Consensus of 14 analyst ratings
Based on 9 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Truist Securities | Maintained | Hold | $135.00 from $81.00 | Aug 13, 2026 |
| BTIG | Downgraded | Buy → Neutral | — | Aug 12, 2026 |
| Mizuho | Downgraded | Outperform → Neutral | $135.00 from $110.00 | Jun 24, 2026 |
| Guggenheim | Downgraded | Buy → Neutral | — | Jun 24, 2026 |
| TD Cowen | Downgraded | Buy → Hold | — | Jun 24, 2026 |
| Stifel | Downgraded | Buy → Hold | $135.00 from $133.00 | Jun 24, 2026 |
| Wedbush | Downgraded | Outperform → Neutral | $135.00 | Jun 23, 2026 |
| UBS | Downgraded | Buy → Neutral | $135.11 from $100.00 | Jun 23, 2026 |
| Citigroup | Downgraded | Buy → Neutral | $135.00 from $125.00 | Jun 23, 2026 |
| RBC Capital | Maintained | Sector Perform | $135.00 from $97.00 | Jun 23, 2026 |
| Deutsche Bank | Downgraded | Buy → Hold | $135.00 from $116.00 | Jun 23, 2026 |
| Canaccord Genuity | Downgraded | Buy → Hold | $135.11 from $130.00 | Jun 22, 2026 |
| RBC Capital | Maintained | Sector Perform | $97.00 from $82.00 | Jun 8, 2026 |
| Wedbush | Maintained | Outperform | $135.00 from $120.00 | May 27, 2026 |
| BTIG | Maintained | Buy | $137.00 | May 27, 2026 |
| Truist Securities | Maintained | Hold | $81.00 from $83.00 | May 27, 2026 |
| Rothschild & Co | Initiated Coverage | Buy | $140.00 | May 1, 2026 |
| Mizuho | Maintained | Outperform | $110.00 from $105.00 | Mar 30, 2026 |
| Guggenheim | Maintained | Buy | $160.00 from $130.00 | Mar 24, 2026 |
| Canaccord Genuity | Maintained | Buy | $130.00 from $89.00 | Mar 24, 2026 |
Frequently asked questions
What is the price target for APGE stock?
The average 12-month analyst price target for Apogee Therapeutics (APGE) is $135.02, with a high estimate of $135.11 and a low of $135.00, across 9 analysts.
Is APGE a buy, sell, or hold?
Analysts covering Apogee Therapeutics currently average a Hold rating: 1 buy, 13 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for APGE?
The average price target of $135.02 implies 0.01% downside from the last price of $135.04.
What is the latest analyst rating on APGE?
On Aug 13, 2026, Truist Securities maintained Apogee Therapeutics at Hold with a price target of $135.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.